Abstract:Introduction: Biological targeting is a key concept in cancer treatment utilized by most therapeutics. Targeted agents that selectively treat diseased tissues while reducing off-target effects to normal tissues are widely used for cancer therapies. However, key hurdles include: (i) a limited number of tumor-specific biomarkers expressed in sufficiently high levels for targeted therapy, (ii) lack of specific biomarkers amenable to targeting, and (iii) current technologies rely on largely protein-based targeting ligands limiting the applications of these therapies due to final conjugates with low payloads. We developed a novel method for tumor-specific delivery by combining metabolic glycoengineering and nanomedicine to engineer targetable chemical groups on cancer cells and enable directed treatments. We hypothesize that increased Fc fragments on the surface of tumor cells can enable antibody-dependent cell mediated cytotoxicity (ADCC) response to tumor cells, providing innate immunotherapy. Materials/Methods: We formulated nanoparticles (NPs) using polyethylene glycol-ply lactic acid-co-glycolic acid (PEG-PLGA). Using the Dolomite microfluidic device, we formed NPs by nanoprecipitation of PEG-PLGA with tetraacetylated N-azidoacetyl-D-mannosamine (Ac4ManNAz), a sialic acid analogue containing a click chemistry group. We targeted this reactive group by functionalizing the Fc fragment with dibenzylcyclooctyne (DBCO). We characterized the NPs using dynamic light scattering (DLS), charge measurements and transmission electron microscopy (TEM). We evaluated toxicity using a cell viability assay and assessed preliminary efficacy with a tumor growth delay study. Results: NP characterization revealed a size of 30-40 nm via DLS, congruent with TEM imaging. Charge measurements ranged from -4 to +4 mV. Toxicity studies revealed no differences in cell viability amongst different treatment groups. Preliminary efficacy studies demonstrated improved tumor growth delay in the cohort of mice treated with a combination of NPs and Fc-DBCO conjugate, as well as a survival benefit. Median OS was 31.5 days for the control groups vs 57.5 days for the combination treated group (p = 0.0067). Conclusion: There is growing interest in harnessing the power of the innate immune response to shape anti-tumor immunity. This is because clinical data demonstrates tumor cells can evade the adaptive immune system through mutations as well as downregulate MHC receptors. One of the most effective innate immune responses is ADCC. To this end, we developed a novel method for tumor-specific delivery of Fc fragments to enhance ADCC. While this data reveals improved tumor growth delay and a survival benefit, the sample size is limited, and a larger study is needed to evaluate the potential benefits of this strategy. Furthermore, correlative studies are needed to identify the mechanism for treatment response. Citation Format: Maureen L. Aliru, Nikhila R. Sultanpuram, Kin Man Au, Tian Zhang, Andrew Z. Wang. Ligand-independent targeting of tumor cells for antibody-dependent cell-mediated cytotoxicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2736.

Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis

Antitumor Effect of FP3 in Combination with Cetuximab on Patient-Derived Tumor Tissue Xenograft Models of Primary Colon Carcinoma and Related Lymphatic and Hepatic Metastases

Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.

Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase

Preclinical Evaluation Of Anti-Ron Antibody-Drug Maytansinoid Conjugates (Anti-Ron Adc) For Targeted Colorectal Cacner Therapy.

Cloning and expression of a novel target fusion protein and its application in anti-tumor therapy

Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors

Genetically Engineered Endostatin-Lidamycin Fusion Proteins Effectively Inhibit Tumor Growth and Metastasis

Preparation of high-penetrability nano antibody fusion protein and application of high-penetrability nano antibody fusion protein in tumor resistance

Abstract 2736: Ligand-independent targeting of tumor cells for antibody-dependent cell-mediated cytotoxicity

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Synthesis, and biological evaluation of EGFR/HER2-NAMPT conjugates for tumor treatment

Tumor-Penetrating Peptide Fused Egfr Single-Domain Antibody Enhances Cancer Drug Penetration into 3d Multicellular Spheroids and Facilitates Effective Gastric Cancer Therapy

Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides

Improved Tumor-Targeting Drug Delivery and Therapeutic Efficacy by Cationic Liposome Modified with Truncated Bfgf Peptide.

Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors

Affibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor-3 Demonstrate Therapeutic Efficacy in Mice Bearing Low Expressing Xenografts

Bivalent EGFR-Targeting DARPin-MMAE Conjugates

Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain